Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed

Executive Summary

US FDA commissioner nominee might employ modular specialists to work with review divisions on issues related to gene therapies, molecularly-targeted drugs, adaptive clinical trial designs, or other complex issues.

Advertisement

Related Content

US FDA Commissioner Confirmation: Gottlieb To Get Questions On Approval Standards, Ties To Industry
CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition
Trump Slams FDA Regulations In Joint Session Of Congress
FDA Gets Broad Exemptions From Federal Hiring Freeze In HHS Memo
Multiple ‘Centers of Excellence’ At US FDA Could Create Review Inefficiencies – Jenkins
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
FDA's Pazdur Jumps Over To New 'Moonshot' Role
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
Don't Rush To Reorganize FDA, McClellan Says
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Topics

Advertisement
UsernamePublicRestriction

Register

PS120263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel